Cited 0 time in
Emerging Therapy in ALS; Immune-inflammatory modulation as an therapeutic strategy of stem cell therapy in ALS: Randomized, parallel-group, phase I/II clinical trial
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김승현 | - |
| dc.date.accessioned | 2021-08-03T06:28:34Z | - |
| dc.date.available | 2021-08-03T06:28:34Z | - |
| dc.date.issued | 2016-05-20 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/36578 | - |
| dc.title | Emerging Therapy in ALS; Immune-inflammatory modulation as an therapeutic strategy of stem cell therapy in ALS: Randomized, parallel-group, phase I/II clinical trial | - |
| dc.type | Conference | - |
| dc.citation.conferenceName | 57th annual meeting of the Japanese Society of Neurology | - |
| dc.citation.conferencePlace | Kobe Portopia Hotel (일본) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
